Integral Health Asset Management, LLC Bei Gene, Ltd. Transaction History

Integral Health Asset Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$141.8 - $181.47 $5.67 Million - $7.26 Million	40,000 New	40,000 $6.26 Million
Q4 2020 Feb 16, 2021	SELL	$221.31 - $316.61 $3.21 Million - $4.59 Million	-14,500 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$189.18 - $286.44 $851,310 - $1.29 Million	4,500 Added 45.0%	14,500 $4.15 Million
Q2 2020 Aug 14, 2020	BUY	$123.9 - $195.41 $1.24 Million - $1.95 Million	10,000 New	10,000 $1.88 Million

251

45.6M

322K

144K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Integral Health Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Integral Health Asset Management, LLC with notifications on news.